Autoimmune Hepatitis, Haemophagocytic Lymphohistiocytosis, and Cardiovascular Complications all Associated with Multiple Sclerosis Drug LEMTRADA
USA- Healthycanadians.gc.ca reports that LEMTRADA, a form of treatment for multiple sclerosis (MS), has been linked to potentially fatal complications in patients. Numerous studies have indicated that LEMTRADA, or alemtuzumab, can cause severe side-effects impacting patients’ immune systems, livers, and cardiovascular systems. If these side-effects are not promptly caught and treated, they can prove fatal.
LEMTRADA is only prescribed to patients after at least two other MS treatments have been tried without success. This drug is administered through an IV infusion over the course of two years. Patients will be treated for five consecutive days in the first year, and one year later, they will be treated for three consecutive days for a total of eight treatments. In some instances, a doctor may recommend another series of three days of treatment one year after the second treatment series.
LEMTRADA has been linked to Autoimmune Hepatitis, which is a form of hepatitis or liver inflammation, that is caused by the body’s immune system attacking the cells in the liver. This condition can result in cirrhosis of the liver or liver failure. Hemophagocytic Lymphohistiocytosis is a severe condition that impacts the immune system and can cause fevers, swollen lymph nodes, systemic inflammation, bruising, and rashes. This condition can be deadly if it is not detected and treated quickly.
Patients should also be on the lookout for symptoms of strokes, which can result from treatment as well as cardiovascular problems, difficulty breathing, and bleeding lungs.
The United States government has not issued a recall of LEMTRADA, and doctors can still prescribe this treatment. Medical practitioners should be aware of the risks associated with this drug and carefully monitor patients who have undergone this type of treatment.
Have you or loved one been harmed by Lemtrada?Click To Get A Free Case Review